Glutarimides for medical treatment
US11802131B2 · kind B2 · utility
2Cited by
19References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 4, 2020 |
| Grant date | Oct 31, 2023 |
| Priority date | — |
| Expiry date | Mar 4, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.